Purinergic contraction of the rat vas deferens in L-NAME-induced hypertension: Effect of sildenafil

Asian Journal of Andrology

Volumn 12, Issue 3, 2010, Pages 415-421

  Gur, Serap ^a   Sikka, Suresh C ^a   Knight, Gillian E ^b   Burnstock, Geoffrey ^b   Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Hypertensive rat; NG nitro L arginine methyl ester; P2X; Purinergic receptors; Sildenafil; Vas deferens

Indexed keywords

ALPHA,BETA METHYLENEADENOSINE DIPHOSPHATE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENYLEPHRINE; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; SILDENAFIL;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONCENTRATION RESPONSE; CONTROLLED STUDY; EJACULATION; ELECTROSTIMULATION; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; RAT; VAS DEFERENS;

ADENOSINE TRIPHOSPHATE; ANIMALS; ELECTRIC STIMULATION; ENZYME INHIBITORS; HYPERTENSION; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NG-NITROARGININE METHYL ESTER; PHENYLEPHRINE; PIPERAZINES; PURINES; PYRIDOXAL PHOSPHATE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P2; SULFONES; VAS DEFERENS; VASODILATOR AGENTS;

EID: 77952048946     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2009.70     Document Type: Article

References (37)

1. Grasso M, Fortuna F, Lania C, Blanco S. Ejaculatory disorders and alpha1-adrenoceptor antagonists therapy: clinical and experimental researches. J Transl Med 2006;4:31.
2. Tambaro S, Ruiu S, Dessi C, Pani L, Ruiu S. Evaluation of tamsulosin and alfuzosin activity in the rat vas deferens: relevance to ejaculation delays. J Pharmacol Exp Ther 2005;312:710-7.
3. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 2007;87:659-797.
4. Medina P, Segarra G, Torondel B, Chuan P, Domenech C, et al. Inhibition of neuroeffector transmission in human vas deferens by sildenafl. Br J Pharmacol 2000;131:871-4.
5. Banks FC, Knight GE, Calvert RC, Thompson CS, Morgan RJ, et al. The purinergic component of human vas deferens contraction. Fertil Steril 2006;85:932-9.
6. Sneddon P, Westfall DP, Colby J, Fedan JS. A pharmacological investigation of the biphasic nature of the contractile response of rabbit and rat vas deferens to feld stimulation. Life Sci 1984;35:1903-12.
7. Meldrum LA, Burnstock G. Evidence that ATP is involved as a co-transmitter in the hypogastric nerve supplying the seminal vesicle of the Guinea pig. Eur J Pharmacol 1985;110:363-6.
8. Bultmann R, Klebroff W, Starke K. Nucleotide-evoked relaxation of rat vas deferens: possible mechanisms. Eur J Pharmacol 2002;436:135-43.
9. Burchardt M, Burchardt T, Baer L, Kiss AJ, Pawar RV, et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000;164:1188-91.
10. Jensen J, Lendorf A, Stimpel H, Frost J, Ibsen H, et al. The prevalence and etiology of impotence in 101 male hypertensive outpatients. Am J Hypertens 1999;12:271-5.
11. Behr-Roussel D, Gorny D, Mevel K, Compagnie S, Kern P, et al. Erectile dysfunction: an early marker for hypertension? A longitudinal study in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2005;288: R276-83.
12. Chitaley K, Webb RC, Dorrance AM, Mills TM. Decreased penile erection in DOCA-salt and stroke prone-spontaneously hypertensive rats. Int J Impot Res 2001;13(Suppl 5): S16-20.
13. Gur S, Kadowitz PJ, Thammasitboon S, Lasky JA, Hellstrom WJ. Characterization of erectile function in monocrotaline-treated pulmonary hypertensive rats. J Androl 2009;305:495-504
14. Caricati-Neto A, Sette M, Jurkiewicz A. Increased density of alpha-adrenoceptors in vas deferens of spontaneously hypertensive rats (SHR), indicated by functional and receptor binding studies. Eur J Pharmacol 1992;218:51-8.
15. Vivas NM, Giraldo J, Tabernero A, Vila E, Badia. use of the operational model of agonism and [3H] prazosin binding to assess altered responsiveness of alpha1-adrenoceptors in the vas deferens of spontaneously hypertensive rat. Naunyn Schmiedebergs Arch Pharmacol 1997;356:383-91.
16. Vidal M, Hicks PE, Langer SZ. Differential effects of alpha-beta-methylene ATP on responses to nerve stimulation in SHR and WKY tail arteries. Naunyn Schmiedebergs Arch Pharmacol 1986;332:384-90.
17. Katsuragi T, Kuratomi L, Sato C, Furukawa T. Hyperreactivity of alpha 1-adrenoceptors, but not of P2X-purinoceptors, in vas deferens of spontaneously hypertensive rats. Eur J Pharmacol 1991;199:303-7.
18. Guitart M, Jimenez M, Giraldo J, Goñalons E, Badia A. Changes in electrophysiological properties in the prostatic portion of vas deferens from spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 2002;366:425-30.
19. Azadzoi KM, Goldstein I. Erectile dysfunction due to atherosclerotic vascular disease: the development of an animal model. J Urol 1992;147:1675-81.
20. Cunha RS, Cabral AM, Vasquez EC. Evidence that the autonomic nervous system plays a major role in the L-NAME-induced hypertension in conscious rats. Am J Hypertens 1993;6:806-9.
21. Rossoni G, Manfredi B, De Gennaro Colonna V, Berti M, Guazzi M, et al. Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. Br J Pharmacol 2007;150:567-76.
22. Burnstock G. The changing face of autonomic neurotransmission. Acta Physiol Scand 1986;126:67-91.
23. Burnstock G. The fifth Heymans memorial lecture-Ghent, February 17, 1990. Co-transmission. Arch Int Pharmacodyn Ther 1990;304:7-33.
24. Bilge SS, Kesim Y, Kurt M, Aksoz E, Celik S. Possible role of sildenafil in inhibiting rat vas deferens contractions by infuencing the purinergic system. Int J Urol 2005;12:829-34.
25. Vetri T, Maio RD, Bonafede G, Passafume L, Postorino A. Neurotransmitters adenosine triphosphate and noradrenaline induce nitric oxide release in rat vas deferens. J Auton Pharmacol 2000;20:133-7.
26. Burnstock, G. Noradrenaline and ATP: cotransmitters and neuromodulators. J Physiol Pharmacol 1995;46:365-84.
27. MacKenzie I, Kirkpatrick KA, Burnstock G. Comparative study of the actions of AP5A and alpha, beta-methylene ATP on nonadrenergic, noncholinergic neurogenic excitation in the guinea-pig vas deferens. Br J Pharmacol 1988;94:699-706.
28. Dunn PM, Zhong Y, Burnstock G. P2X receptors in peripheral neurons. Prog Neurobiol 2001;65:107-34.
29. Wirkner K, Sperlagh B, Illes P. P2X3 receptor involvement in pain states. Mol Neurobiol 2007;36:165-83.
30. Trinchieri A, Magri V, Cariani L, Bonamore R, Restelli A, et al. Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome. Arch Ital Urol An-drol 2007;79:67-70.
31. Cockayne DA, Hamilton SG, Zhu QM, Dunn PM, Zhong, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 2000;407:1011-5.
32. Ralevic V, Burnstock G. Receptors for purines and pyri-midines. Pharmacol Rev 1998;50:413.
33. Lee HY, Bardini M, Burnstock G. P2X receptor immuno-reactivity in the male genital organs of the rat. Cell Tissue Res 2000;300:321-30.
34. Buvinic S, Briones R, Huidobro-Toro JP. P2Y (1) and P2Y (2) receptors are coupled to the NO/cGMP pathway to vasodilate the rat arterial mesenteric bed. Br J Pharmacol 2002;136:847.
35. + in rat vas deferens. Eur J Pharmacol 2003;470:37-43.
36. Turla MB, Webb RC. Enhanced vascular reactivity to protein kinase C activators in genetically hypertensive rats. Hypertension 1987;9: III150-4.
37. Abdel-Hamid IA. Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action. Drugs 2004;64:13-26.